CA
NZ
UK
AU
IND
US
…
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and is based in Austin, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Establishment Labs manufactures silicone breast implants and implant-tracking safety technology for aesthetic and reconstructive surgery via direct and distributor channels. Long-term growth may be driven by expanding procedure demand, U.S. market penetration and uptake of its proprietary implant features; investors may find exposure to a differentiated product platform and geographic expansion attractive.
Material risks include regulatory and product-safety scrutiny with potential liability, strong competition from large implant makers and execution risk in scaling U.S. commercialization alongside a concentrated manufacturing base.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -58.02M | -84.63M | -78.58M | -72.82M | -39.71M |
| Net income | -51.06M | -84.60M | -78.50M | -75.21M | -41.14M |
| Selling general administrative | 165.07M | 139.81M | 143.54M | 125.98M | 92.23M |
| Gross profit | 146.31M | 109.53M | 106.98M | 106.59M | 85.40M |
| Reconciled depreciation | 10.47M | 7.58M | 4.63M | 4.34M | 4.12M |
| Ebit | - | -63.80M | -63.19M | -39.66M | -25.14M |
| Ebitda | -32.77M | -56.22M | -58.31M | -42.75M | -31.39M |
| Depreciation and amortization | - | 7.58M | 4.88M | -3.09M | -6.25M |
| Non operating income net other | - | - | - | -21.41M | -5.51M |
| Operating income | -39.01M | -49.99M | -65.03M | -39.66M | -25.14M |
| Other operating expenses | 250.08M | 216.01M | 230.18M | 201.36M | 151.82M |
| Interest expense | 25.26M | 20.83M | 15.39M | 11.76M | 9.06M |
| Tax provision | -6.96M | -0.03M | 3.24M | 2.38M | 1.43M |
| Interest income | 0.42M | 1.48M | 0.54M | 0.09M | 0.02M |
| Net interest income | -24.83M | -19.35M | -12.71M | -11.67M | -9.04M |
| Income tax expense | -6.96M | -0.03M | -0.08M | 2.38M | 1.43M |
| Total revenue | 211.08M | 166.03M | 165.15M | 161.70M | 126.68M |
| Total operating expenses | 185.32M | 159.51M | 172.00M | 146.25M | 110.54M |
| Cost of revenue | 64.77M | 56.50M | 58.17M | 55.10M | 41.28M |
| Total other income expense net | -19.01M | -34.64M | -13.56M | -33.17M | -14.57M |
| Net income from continuing ops | -51.06M | -84.60M | -71.52M | -75.21M | -41.14M |
| Net income applicable to common shares | - | - | - | -75.21M | -41.14M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 357.17M | 346.83M | 268.64M | 211.06M | 139.53M |
| Intangible assets | 9.94M | 11.68M | 7.99M | 4.61M | 4.37M |
| Other current assets | 11.26M | 8.92M | 8.01M | 11.54M | 2.64M |
| Total liab | 333.62M | 293.74M | 250.25M | 219.25M | 88.79M |
| Total stockholder equity | 23.55M | 53.09M | 18.39M | -8.19M | 50.74M |
| Other current liab | 24.91M | 34.23M | 12.92M | 16.55M | 16.24M |
| Common stock | 433.38M | 420.36M | 315.63M | 223.64M | 219.74M |
| Capital stock | 433.38M | 420.36M | 315.63M | 223.64M | 219.74M |
| Retained earnings | -495.76M | -444.69M | -360.10M | -281.59M | -206.38M |
| Other liab | - | - | - | 1.63M | 3.10M |
| Good will | 1.21M | 1.21M | 0.47M | 0.47M | 0.47M |
| Other assets | - | - | - | 1.29M | 0.56M |
| Cash | 75.57M | 90.35M | 40.03M | 66.36M | 53.41M |
| Total current liabilities | 82.14M | 68.28M | 57.15M | 38.96M | 31.89M |
| Current deferred revenue | - | 1.75M | 1.84M | 1.69M | 0.77M |
| Net debt | 188.90M | 134.95M | 152.19M | 112.31M | 0.39M |
| Short term debt | 14.12M | 1.51M | 0.77M | 0.69M | 0.40M |
| Short long term debt | 12.41M | - | - | - | - |
| Short long term debt total | 264.47M | 225.29M | 192.22M | 178.66M | 53.81M |
| Other stockholder equity | 84.77M | 74.14M | 60.89M | 47.06M | 33.73M |
| Property plant equipment | - | - | - | 51.09M | 20.86M |
| Total current assets | 249.94M | 243.04M | 174.90M | 149.90M | 113.27M |
| Net tangible assets | - | - | - | -13.26M | 45.90M |
| Net receivables | 77.50M | 65.00M | 46.92M | 35.42M | 24.44M |
| Long term debt | 247.52M | 219.58M | 188.74M | 175.46M | 51.91M |
| Inventory | 85.61M | 78.77M | 79.94M | 36.58M | 28.41M |
| Accounts payable | 43.11M | 44.76M | 41.62M | 20.03M | 14.47M |
| Accumulated other comprehensive income | 1.16M | 3.29M | 1.96M | 2.71M | 3.66M |
| Common stock total equity | - | - | - | 223.64M | 219.74M |
| Retained earnings total equity | - | - | - | -281.59M | -206.38M |
| Treasury stock | - | - | - | - | -2.85M |
| Non currrent assets other | 16.12M | 7.31M | 4.70M | 1.29M | 0.56M |
| Non current assets total | 107.23M | 103.79M | 93.74M | 61.16M | 26.26M |
| Capital lease obligations | 4.53M | 5.72M | 3.48M | 3.20M | 2.30M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -15.61M | -24.55M | -34.79M | -7.16M |
| Change to liabilities | - | - | - | 7.31M | 4.96M |
| Total cashflows from investing activities | -7.03M | - | - | -34.79M | -7.16M |
| Net borrowings | 33.48M | - | - | 96.41M | -0.17M |
| Total cash from financing activities | 40.43M | 125.89M | 86.23M | 100.25M | 4.05M |
| Change to operating activities | - | - | - | -2.69M | 2.94M |
| Net income | -51.06M | -84.60M | -78.50M | -75.21M | -41.14M |
| Change in cash | -14.78M | 50.31M | -26.32M | 12.94M | -31.11M |
| Begin period cash flow | 90.35M | 40.03M | 66.36M | 53.41M | 84.52M |
| End period cash flow | 75.57M | 90.35M | 40.03M | 66.36M | 53.41M |
| Total cash from operating activities | -50.89M | -58.52M | -88.51M | -52.17M | -27.53M |
| Issuance of capital stock | 0.00M | 99.48M | 84.54M | 84.54M | 0.00M |
| Depreciation | -9.56M | 7.58M | 4.88M | 4.34M | 4.12M |
| Other cashflows from investing activities | -2.66M | -9.45M | -1.33M | -0.53M | -0.43M |
| Dividends paid | - | - | - | 3.87M | 4.23M |
| Change to inventory | -7.06M | -0.47M | -42.23M | -10.90M | -7.64M |
| Change to account receivables | -11.47M | -26.28M | -11.56M | -12.33M | -6.70M |
| Sale purchase of stock | - | - | -0.48M | -0.00M | -0.36M |
| Other cashflows from financing activities | -0.64M | 1.94M | 3.86M | 3.87M | 4.23M |
| Change to netincome | - | - | - | 22.05M | 13.85M |
| Capital expenditures | 6.05M | 8.53M | 24.55M | 34.27M | 6.73M |
| Change receivables | - | - | - | -12.33M | -6.70M |
| Cash flows other operating | - | - | - | 8.79M | 11.87M |
| Cash and cash equivalents changes | - | - | - | 13.30M | -30.64M |
| Change in working capital | -13.17M | -15.50M | -34.13M | -21.54M | -6.44M |
| Stock based compensation | -11.41M | 14.40M | 14.36M | 13.36M | 10.41M |
| Other non cash items | 27.36M | 20.81M | 8.58M | 26.80M | 5.51M |
| Free cash flow | -56.94M | -64.63M | -113.06M | -86.43M | -34.26M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ESTA Establishment Labs Holdings Inc |
-6.24 9.12% |
62.17 | - | 217.39 | 8.67 | 99.20 | 9.50 | -26.29 |
| ABT Abbott Laboratories |
1.18 1.13% |
105.75 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.21 0.22% |
96.90 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-17.80 5.71% |
293.95 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and is based in Austin, Texas.
11401 century oaks terrace, Austin, TX, United States, 78758
800 924 5072
1004
| Name | Title | Year Born |
|---|---|---|
| Mr. Juan Jose Chacon Quiros | Founder, CEO & Exec. Director | 1972 |
| Mr. Rajbir Singh Denhoy | Chief Financial Officer | 1970 |
| Mr. Paul D. Rodio | Chief Operating Officer | 1966 |
| Mr. Roberto de Mezerville | Chief Technology Officer | 1981 |
| Mr. S. Ross Mansbach | Gen. Counsel & Chief Compliance Officer | NA |
| Mr. Jeffrey Clark Bettinger | Global Head of People | NA |
| Mr. Salvador Santos Dada | Chief Operating Officer (Medical Leave of Absence) | 1983 |
| Dr. Heather Brennan | Head of U.S. Commercial Operations | NA |
| Ms. Neeta Toprani | Corp. Sec. | NA |
| Mr. Juan Jose Chacon Quiros | Founder, CEO & Executive Director | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.38%
Communication Services
-0.47%
Consumer Cyclical
-0.18%
Consumer Defensive
+0.19%
Energy
-0.03%
Financial Services
-0.58%
Financials
+2.59%
Healthcare
-1.10%
Industrials
-0.82%
Real Estate
-0.23%
Technology
-2.51%
Utilities
-0.09%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...